Zürcher Kantonalbank

Cantonal bank that takes stakes in Swiss start-ups through its venture capital activity.

Profile being verified

Stage
Pre-seed to growth across recorded rounds
Ticket
Tickets not disclosed; recorded rounds of CHF 1.7 M to USD 25 M
Sector
Deep tech, biotech, cleantech
Location
Not specified
Tracked rounds
15

What they look for

An article (CompPair, February 2026) mentions the venture capital arm of ZKB, represented by investment manager Yves Becker. It co-led Haelixa's pre-Series A round with Verve Ventures and frequently appears as an existing investor (BTRY, Cosaic, Piomic Medical). Swisscanto, the growth fund of ZKB's asset management division, led Piomic Medical's round with a CHF 10 M commitment.

Recent investments

Recorded Swiss rounds: arcoris bio (seed, CHF 6.3 M, November 2025), BTRY (seed, CHF 4.6 M, November 2025), Riverkin (stage not specified, CHF 1.7 M, November 2025), Haelixa (pre-Series A, EUR 2 M, February 2026, co-lead), CompPair Technologies (stage not specified, amount not disclosed, February 2026), Clee Medical (seed, amount not disclosed, February 2026), Alithea Genomics (seed, CHF 6.9 M, March 2026), Seprify (Series A, EUR 13.4 M, March 2026), Cosaic (seed, USD 6 M, April 2026), CCRAFT (stage not specified, USD 7.8 M, July 2026), Immitra Bio (pre-seed, CHF 2.4 M, July 2026), DataHow (Series A, amount not disclosed, September 2026), Piomic Medical (growth, USD 25 M, September 2026), Cotierra (stage not specified, USD 3 M, September 2026), UniSieve (Series A, USD 9 M, October 2026).

Rounds tracked by FundSwiss